Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu

Life Sciences

Volumn 92, Issue 17-19, 2013, Pages 896-902

  Zhang, Yi ^a   Liu, Guangpu ^b   Lin, Changwei ^c   Liao, Guoqing ^a   Tang, Bo ^d,e  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b XUZHOU CENTRAL HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d GUILIN MEDICAL UNIVERSITY   (China)

^e DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

EZH2; Hepatocellular carcinoma; MDR1; Multidrug resistance; RNA interference

Indexed keywords

FLUOROURACIL; TETRAZOLIUM; TRANSCRIPTION FACTOR EZH2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; FLOW CYTOMETRY; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CANCER; MASS SPECTROMETRY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE SILENCING; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84876789029     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.03.010     Document Type: Article

References (20)

1. P.H. Abbosh, J.S. Montgomery, J.A. Starkey, M. Novotny, E.G. Zuhowski, and M.J. Egorin Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells Cancer Res 66 2006 5582 5591 (Pubitemid 43927108)
2. J. Bartek, and J. Lukas Mammalian G1- and S-phase checkpoints in response to DNA damage Curr Opin Cell Biol 13 2001 738 747 (Pubitemid 33042735)
3. R. Cao, L. Wang, H. Wang, L. Xia, H. Erdjument-Bromage, and P. Tempst Role of histone H3 lysine 27 methylation in Polycomb-group silencing Science 298 2002 1039 1043 (Pubitemid 35247314)
4. C. Cardoso, C. Mignon, G. Hetet, B. Grandchamps, M. Fontes, and L. Colleaux The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders Eur J Hum Genet 8 2000 174 180 (Pubitemid 30189860)
5. H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, and W.W. Bassett CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer Cancer Res 64 2004 5956 5962 (Pubitemid 39129391)
6. B. Fussbroich, N. Wagener, S. Macher-Goeppinger, A. Benner, M. Fälth, and H. Sültmann EZH2 depletion blocks the proliferation of colon cancer cells PLoS One 6 2011 e21651
7. S. Hu, L. Yu, Z. Li, Y. Shen, J. Wang, and J. Cai Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo Cancer Biol Ther 10 2010 788 795
8. K. Koike, A. Takaki, M. Tatsukawa, M. Suzuki, H. Shiraha, and Y. Iwasaki Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines Int J Oncol 29 2006 1253 1261
9. B. Li, T. Ye, L. Zhao, D.H. Li, X.H. Gou, and L.Y. Zhao Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells Hepatobiliary Pancreat Dis Int 5 2006 552 559 (Pubitemid 44782095)
10. K.M. McGarvey, E. Greene, J.A. Fahrner, T. Jenuwein, and S.B. Baylin DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2 Cancer Res 67 2007 5097 5102 (Pubitemid 46997244)
11. M. Nakamura, H. Nagano, M. Sakon, T. Yamamoto, H. Ota, and H. Wada Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro J Hepatol 46 2007 77 88 (Pubitemid 44827417)
12. K. Okuda Hepatocellular carcinoma J Hepatol 32 2000 225 237 (Pubitemid 30123637)
13. A.V. Ougolkov, V.N. Bilim, and D.D. Billadeau Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2 Clin Cancer Res 14 2008 6790 6796
14. F.M. Raaphorst, C.J. Meijer, E. Fieret, T. Blokzijl, E. Mommers, and H. Buerger Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene Neoplasia 5 2003 481 488 (Pubitemid 38045085)
15. R.G. Sewalt, J. van der Vlag, M.J. Gunster, K.M. Hamer, J.L. den Blaauwen, and D.P. Satijn Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes Mol Cell Biol 18 1998 3586 3595 (Pubitemid 28240531)
16. K. Takara, T. Sakaeda, and K. Okumura An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy Curr Pharm Des 12 2006 273 286
17. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, and M.G. Sanda The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
18. E. Viré, C. Brenner, R. Deplus, L. Blanchon, M. Fraga, and C. Didelot The Polycomb group protein EZH2 directly controls DNA methylation Nature 439 2006 871 874 (Pubitemid 43255707)
19. S. Warmann, G. Göhring, B. Teichmann, H. Geerlings, T. Pietsch, and J. Fuchs P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors Anticancer Res 23 2003 4607 4611 (Pubitemid 38173874)
20. B.J. Zhai, Z.Y. Shao, C.L. Zhao, K. Hu, and F. Wu Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice World J Gastroenterol 12 2006 6614 6619 (Pubitemid 44794937)